Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the ona domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/risezcom/public_html/cord-blood.org.uk/wp-includes/functions.php on line 6170
Revolutionising Transplants: The Promise of Omidubicel - Cord Blood

Cord Blood

and Stem Cell Banking

Revolutionising Transplants: The Promise of Omidubicel

Image of blood cells

Umbilical cord blood transplants (often shortened to UCB or CBT) have been around for a while and have acted as a life-saving alternative for many patients. Especially for those who don’t have a genetically matched donor available.

Here’s a quick fact: Only about 30% of patients with high-risk blood cancers have a sibling that’s a perfect genetic match for transplant needs. So, many turn to alternatives like mismatched donors or UCB. While UCB transplants offer unique benefits, like a superb effect against leukemia, there are some drawbacks, primarily due to the lower cell dose in UCB. This can lead to slow recovery post-transplant and an immature immune system that’s more susceptible to infections.

But here’s where the game changes: Enter omidubicel.

Omidubicel: A Game-Changer in Transplantation

Omidubicel isn’t just any UCB product. It’s been expanded in the lab to address many of the challenges associated with standard UCB transplants. Clinical trials have showcased its ability to speed up recovery post-transplant, fortify the immune system, and reduce the risk of infections. Based on these impressive results, it has received the green light from the U.S. Food & Drug Administration.

But how did we get here?

Journey of UCB Transplants

The story began in 1988 when the first UCB transplant was carried out on a 5-year old boy with a rare condition called Fanconi anemia. This pioneering transplant used the umbilical cord blood from his sibling (who wasn’t affected by Fanconi anemia). This success proved that UCB cells have incredible potential. Since then, UCB transplants have skyrocketed in popularity, with over 40,000 procedures performed globally.

One major advantage of UCB cells is that they’re “newbies” in the immune world. This means they don’t need as stringent a genetic match as other transplant sources, widening the donor pool. Plus, they’re readily available since they’re often stored and frozen after being collected, reducing wait times for patients in urgent need.

But, as mentioned earlier, there are challenges. The main one being the lower cell count in UCB, which can slow down the patient’s recovery and leave them more exposed to infections.

The Role of Omidubicel

To address the challenges of UCB transplants, researchers have spent decades trying to improve the number and functionality of UCB cells. And that’s where omidubicel shines. It uses a compound called nicotinamide, combined with a cocktail of other molecules, to boost the numbers and efficiency of these cells. The end result? A product that’s not only more potent than standard UCB but also offers faster and more efficient recovery after transplant.

The Future of Transplants

While omidubicel is undeniably a massive step forward, the journey doesn’t stop here. Researchers continue to explore ways to further enhance UCB transplants and expand their applications.

For now, patients and doctors can look at omidubicel with hope. It represents the potential to transform transplantation for many patients, offering them a better, faster route to recovery.